MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Topic
HIV Research and Treatment
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

3,719 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
3,719 works in the cohort · of 4,299,418page 31 of 75

Labels cover 13 of 3,719 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 3,719 of 3,719 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

afffundunlabeled
Maraviroc, as a Switch Option, in HIV-1–infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study
Sarah Pett, Janaki Amin, A Horban, Jaime Andrade‐Villanueva, Marcelo Losso, Norma Porteiro +22 more
2016· article· en· Clinical Infectious Diseases· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
23
citations
afffundunlabeled
Novel Acylguanidine-Based Inhibitor of HIV-1
Philip Mwimanzi, Ian Tietjen, Scott C. Miller, Aniqa Shahid, Kyle D. Cobarrubias, Natalie N. Kinloch +6 more
2016· article· en· Journal of Virology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
22
citations
afffundno abstractunlabeled
Targeting Th17 cells in HIV-1 remission/cure interventions
Augustine Fert, Laurence Raymond Marchand, Tomas Raul Wiche Salinas, Petronela Ancuța
2022· review· en· Trends in Immunology· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
22
citations
affunlabeled
CCR5 as Target for HIV-1 Gene Therapy
Reza Nazari, Sadhna Joshi
2008· review· en· Current Gene Therapy· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
22
citations
afffundunlabeled
The brain and HAART
Rick B. Meeker, Eugene L. Asahchop, Christopher Power
2014· review· en· Current Opinion in HIV and AIDS· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
22
citations
affunlabeled
Viral dynamics of HIV-1 with CTL immune response
Aiping Wang, Michael Y. Li
2020· article· en· Discrete and Continuous Dynamical Systems - B· Immunology and Microbiology
machine prediction:candidate · noneconsensus · none
22
citations

How this was built: Screen · Findings · About